Ken Griffin Moleculin Biotech, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.41 - $0.86 $26,507 - $55,600
64,652 New
64,652 $55,000
Q1 2023

May 15, 2023
BUY
$0.9 - $1.34 $13,860 - $20,636
15,400 Added 93.19%
31,926 $30,000
Q4 2022

Feb 14, 2023
BUY
$0.85 - $16.65 $2,460 - $48,201
2,895 Added 21.24%
16,526 $17,000
Q3 2022

Nov 14, 2022
BUY
$1.15 - $17.4 $15,675 - $237,179
13,631 New
13,631 $14,000

Others Institutions Holding MBRX

# of Institutions
2
Shares Held
3.35K
Call Options Held
0
Put Options Held
0
View Full List

About Moleculin Biotech, Inc.

MBRX Quotes by TradingView
  • Ticker MBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,606,700
  • Market Cap $67.5M
  • Description
  • Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....
More about MBRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email